Liselot M. Mus

Liselot M. Mus

Auto-generated profile, based on publicly available information

Liselot M. Mus

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2017 in Nature Methods
Verified
Journal Article
Closed access
ECEV-TRACK Consortium
EV-TRACK Consortium
JDJan Van Deun
Jan Van Deun
PMPieter Mestdagh
Pieter Mestdagh
PAPatrizia Agostinis
Patrizia Agostinis
ÖAÖzden Akay
Özden Akay
AHAn Hendrix
An Hendrix

15 July 2022 in Science Advances
Verified
Journal Article
Open access
CNCarolina Nunes
Carolina Nunes
LDLisa Depestel
Lisa Depestel
LMLiselot Mus
Liselot Mus
KKKaylee M. Keller
Kaylee M. Keller
LDLouis Delhaye
Louis Delhaye
FSFrank Speleman
Frank Speleman
High-risk neuroblastoma, a pediatric tumor originating from the sympathetic nervous system, has a low mutation load but highly recurrent somatic DNA copy number variants. Previously, segmental gains and/or amplifications allowed identification of drivers for neuroblastoma development. Using this approach, combined with gene dosage impact on expression and survival, we identified ribonucleotide reductase subunit M2 (RRM2) as a candidate dependency factor further supported by growth inhibition upon in vitro knockdown and accelerated tumor formation in a neuroblastoma zebrafish model coexpressing human RRM2 with MYCN. Forced RRM2 induction alleviates excessive replicative stress induced by CHK1 inhibition, while high RRM2 expression in human neuroblastomas correlates with high CHK1 activity. MYCN-driven zebrafish tumors with RRM2 co-overexpression exhibit differentially expressed DNA repair genes in keeping with enhanced ATR-CHK1 signaling activity. In vitro, RRM2 inhibition enhances intrinsic replication stress checkpoint addiction. Last, combinatorial RRM2-CHK1 inhibition acts synergistic in high-risk neuroblastoma cell lines and patient-derived xenograft models, illustrating the therapeutic potential.

11 December 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
SCShana Claeys
Shana Claeys
GDGeertrui Denecker
Geertrui Denecker
KDKaat Durinck
Kaat Durinck
BDBieke Decaesteker
Bieke Decaesteker
LMLiselot M. Mus
Liselot M. Mus
FSFrank Speleman
Frank Speleman

14 January 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LMLiselot M. Mus
Liselot M. Mus
ILIrina Lambertz
Irina Lambertz
SCShana Claeys
Shana Claeys
CKCandy Kumps
Candy Kumps
WLWouter Van Loocke
Wouter Van Loocke
FSFrank Speleman
Frank Speleman
Neuroblastoma is an aggressive childhood cancer arising from sympatho-adrenergic neuronal progenitors. The low survival rates for high-risk disease point to an urgent need for novel targeted therapeutic approaches. Detailed molecular characterization of the neuroblastoma genomic landscape indicates that ALK-activating mutations are present in 10% of primary tumours. Together with other mutations causing RAS/MAPK pathway activation, ALK mutations are also enriched in relapsed cases and ALK activation was shown to accelerate MYCN-driven tumour formation through hitherto unknown ALK-driven target genes. To gain further insight into how ALK contributes to neuroblastoma aggressiveness, we searched for known oncogenes in our previously reported ALK-driven gene signature. We identified ETV5, a bona fide oncogene in prostate cancer, as robustly upregulated in neuroblastoma cells harbouring ALK mutations, and show high ETV5 levels downstream of the RAS/MAPK axis. Increased ETV5 expression significantly impacted migration, invasion and colony formation in vitro, and ETV5 knockdown reduced proliferation in a murine xenograft model. We also established a gene signature associated with ETV5 knockdown that correlates with poor patient survival. Taken together, our data highlight ETV5 as an intrinsic component of oncogenic ALK-driven signalling through the MAPK axis and propose that ETV5 upregulation in neuroblastoma may contribute to tumour aggressiveness.

30 November 2016 in Scientific Reports
Verified
Journal Article
Open access
AGAlan Van Goethem
Alan Van Goethem
NYNurten Yigit
Nurten Yigit
CECeline Everaert
Celine Everaert
MMMyrthala Moreno-Smith
Myrthala Moreno-Smith
LMLiselot M. Mus
Liselot M. Mus
JVJo Vandesompele
Jo Vandesompele
The ongoing ascent of sequencing technologies has enabled researchers to gain unprecedented insights into the RNA content of biological samples. MiRNAs, a class of small non-coding RNAs, play a pivotal role in regulating gene expression. The discovery that miRNAs are stably present in circulation has spiked interest in their potential use as minimally-invasive biomarkers. However, sequencing of blood-derived samples (serum, plasma) is challenging due to the often low RNA concentration, poor RNA quality and the presence of highly abundant RNAs that dominate sequencing libraries. In murine serum for example, the high abundance of tRNA-derived small RNAs called 5′ tRNA halves hampers the detection of other small RNAs, like miRNAs. We therefore evaluated two complementary approaches for targeted depletion of 5′ tRNA halves in murine serum samples. Using a protocol based on biotinylated DNA probes and streptavidin coated magnetic beads we were able to selectively deplete 95% of the targeted 5′ tRNA half molecules. This allowed an unbiased enrichment of the miRNA fraction resulting in a 6-fold increase of mapped miRNA reads and 60% more unique miRNAs detected. Moreover, when comparing miRNA levels in tumor-carrying versus tumor-free mice, we observed a three-fold increase in differentially expressed miRNAs.

18 December 2020 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
LMLiselot M. Mus
Liselot M. Mus
SHStéphane Van Haver
Stéphane Van Haver
MPMina Popovic
Mina Popovic
WTWim Trypsteen
Wim Trypsteen
SLSteve Lefever
Steve Lefever
FSFrank Speleman
Frank Speleman